Titre :

Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab

Auteur(s) :

Soria, Angele [Auteur]
Sorbonne Université [SU]
Du Thanh, Aurelie [Auteur]
Seneschal, Julien [Auteur]
Jachiet, Marie [Auteur]
Barbarot, Sebastien [Auteur]
staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

JAMA Dermatology

Nom court de la revue :

JAMA Dermatol

Numéro :

155

Date de publication :

2019-09-04

ISSN :

2168-6084

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 ...
Lire la suite >The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:26:29Z
2024-02-06T11:45:40Z